搜索优化
English
全部
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
12 天
遗传了EGFR基因R776H突变?这个48岁女人肺部出现了多个肿瘤病灶
2022年7月,一名48岁女性因为持续咳嗽而进行胸部X光检查,发现双侧肺部有多发结节,她接受了胸部计算机断层扫描(CT),结果证实存在多个双侧磨玻璃样混浊,并且肺右下叶基底外侧段存在一个18毫米的实性结节。支气管镜检查显示正常,在支气管冲洗液中检测到 ...
1 天
on MSN
Biomarker predicts KRASG12C inhibitor success in lung cancer treatment
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...
FierceBiotech
4 天
Cullinan plans approval application for lung cancer drug this year based on phase 2 win
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
11 天
无需化疗一线治疗肺癌,强生双抗组合疗法获欧盟批准
欧盟委员会的批准基于3期临床试验MARIPOSA的结果。该研究评估了Lazcluze联合Rybrevant,与活性对照osimertinib相比,一线治疗携带上述EGFR变异的NSCLC患者的疗效。分析显示,Rybrevant与Lazcluze联用,与活性对照药物相比,可将疾病进展或死亡风险降低30%。联合疗法与活性对照药物组患者的中位无进展生存期(PFS)分别为23.7个月与16.6个月。此外, ...
Targeted Oncology
12 天
Kim Evaluates New Regimens for EGFR+ Lung Cancer
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
3 天
Cancer Cells Tricked To Destroy Themselves By Genetic Editing
Cancer still eludes treatment, and tumors frequently evolve resistance mechanisms to get around medications. By making cancer ...
EurekAlert!
2 天
Moffitt study finds key biomarker to predict KRASG12C inhibitor effectiveness in lung cancer
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...
Targeted Oncology
11 天
Evolution of Personalized Cancer Care With Molecular Profiling
Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...
12 天
on MSN
Daily pill on NHS offers new hope for hundreds with lung cancer
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
来自MSN
12 天
Daily pill for lung cancer to be made routinely available on the NHS
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery when taken ...
3 天
on MSN
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
GlobalData on MSN
10 天
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and Imfinzi
Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈